SG11201509173WA - Alpha adrenergic agonists for in the treatment of tissue trauma - Google Patents

Alpha adrenergic agonists for in the treatment of tissue trauma

Info

Publication number
SG11201509173WA
SG11201509173WA SG11201509173WA SG11201509173WA SG11201509173WA SG 11201509173W A SG11201509173W A SG 11201509173WA SG 11201509173W A SG11201509173W A SG 11201509173WA SG 11201509173W A SG11201509173W A SG 11201509173WA SG 11201509173W A SG11201509173W A SG 11201509173WA
Authority
SG
Singapore
Prior art keywords
treatment
adrenergic agonists
alpha adrenergic
tissue trauma
trauma
Prior art date
Application number
SG11201509173WA
Other languages
English (en)
Inventor
Daniel W Gil
Lydia L Andrews-Jones
Edward C Hsia
Mingting Tian
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG11201509173WA publication Critical patent/SG11201509173WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201509173WA 2013-05-06 2014-05-05 Alpha adrenergic agonists for in the treatment of tissue trauma SG11201509173WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819927P 2013-05-06 2013-05-06
PCT/US2014/036778 WO2014182610A2 (en) 2013-05-06 2014-05-05 Alpha adrenergic agonists for the treatment of tissue trauma

Publications (1)

Publication Number Publication Date
SG11201509173WA true SG11201509173WA (en) 2015-12-30

Family

ID=50928274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509173WA SG11201509173WA (en) 2013-05-06 2014-05-05 Alpha adrenergic agonists for in the treatment of tissue trauma

Country Status (14)

Country Link
US (2) US20140329874A1 (ru)
EP (1) EP2994120B1 (ru)
JP (1) JP2016518409A (ru)
KR (1) KR20160005351A (ru)
CN (1) CN105188691A (ru)
AU (1) AU2014262960A1 (ru)
BR (1) BR112015027984A2 (ru)
CA (1) CA2911472A1 (ru)
ES (1) ES2765264T3 (ru)
HK (1) HK1222558A1 (ru)
MX (1) MX2015015379A (ru)
RU (1) RU2015148910A (ru)
SG (1) SG11201509173WA (ru)
WO (1) WO2014182610A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525553A (ja) * 2013-07-26 2016-08-25 ガルデルマ・リサーチ・アンド・デヴェロップメント 皮膚肥厚の治療法
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
WO2017132214A1 (en) * 2016-01-26 2017-08-03 Scherer Warren J Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
US20190240172A1 (en) * 2016-10-21 2019-08-08 Cellvertics Co., Ltd. Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midodrine or pharmaceutically acceptable salt thereof as active ingredient
CN113197848B (zh) * 2021-05-24 2023-06-09 成都欣捷高新技术开发股份有限公司 一种重酒石酸间羟胺药物组合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1282855B (de) * 1966-08-27 1968-11-14 Merck Ag E Kosmetisches Lichtschutzmittel
US6009234A (en) * 1995-04-14 1999-12-28 Kabushiki Kaisha Toshiba Method of reproducing information
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
EP2055719A1 (en) * 2007-11-05 2009-05-06 Total Petrochemicals Research Feluy Optimisation of the ethylene polymerisation process
WO2009061431A2 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
NZ703808A (en) * 2010-01-08 2016-01-29 Recro Pharma Inc Topical transdermal dexmedetomidine compositions and methods of use thereof
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
PT2645993T (pt) * 2010-12-03 2017-03-03 Allergan Inc Composições de creme farmacêutico compreendendo oximetazolina
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013010032A1 (en) * 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Also Published As

Publication number Publication date
MX2015015379A (es) 2016-03-04
WO2014182610A2 (en) 2014-11-13
CA2911472A1 (en) 2014-11-13
RU2015148910A (ru) 2017-06-13
CN105188691A (zh) 2015-12-23
EP2994120A2 (en) 2016-03-16
US20140329874A1 (en) 2014-11-06
WO2014182610A3 (en) 2014-12-31
HK1222558A1 (zh) 2017-07-07
KR20160005351A (ko) 2016-01-14
ES2765264T3 (es) 2020-06-08
BR112015027984A2 (pt) 2017-09-05
AU2014262960A1 (en) 2015-11-26
JP2016518409A (ja) 2016-06-23
US20200054608A1 (en) 2020-02-20
EP2994120B1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
IL285843A (en) Ibrutinib for use in the treatment of graft-versus-host disease
HK1222530A1 (zh) 用於皮膚處理的微閉合及相關方法
IL243976A0 (en) kdm1a inhibitors for disease treatment
HK1250468A1 (zh) 用於執行體內外科手術的外科系統
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2956049A4 (en) SYSTEM FOR NON-INVASIVE DETERMINATION OF THE PRESENCE OF WATER IN A TISSUE
IL239007B (en) Eribulin for use in the treatment of breast cancer
GB2516051B (en) Surgical tables
IL245647A0 (en) surgical gauze
EP3061452A4 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
HK1222562A1 (zh) 用於醫學診斷的組合物及方法
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
HK1222558A1 (zh) 用於治療組織創傷的α-腎上腺素能激動劑
PL2777671T3 (pl) Stół dla pacjenta
IL236823A0 (en) Preparations for use in the treatment of bone defects
LT3044229T (lt) Peptidai, skirti panaudoti gydant burnos mukozitą
GB201404355D0 (en) Improvements in surgical instruments
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
GB201511341D0 (en) Apparatus adapted for use in clinically invasive procedures
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
GB201317331D0 (en) Device for use in orthopaedic surgery
IL240710A0 (en) Administration of sdf-1 to treat ischemic tissue
HUP1300720A2 (hu) Gyógyászati készítmények sebgyógyulás elõsegítésére
EP3104863C0 (en) SALICYLATE FOR USE IN THE TREATMENT OF CANCER
GB201300815D0 (en) Device for use in surgical procedure